Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | BCAT2 | O15382 | 5/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.35 |
| ▸ | FEN1 | P39748 | 1/20 | 0.35 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4720274 | 0.88 | BCAT2 (0.43) | HPGDBCAT2MAPTKDM4ELMNA | |
| SCHEMBL4720475 | 0.83 | BCAT2 (0.42) | HPGDBCAT2MAPTKDM4ELMNA | |
| SCHEMBL290869 | 0.82 | HPGD (0.48) | HPGDBCAT2MAPTLMNAHTT | |
| SCHEMBL27614384 | 0.80 | BCAT2 (0.41) | HPGDBCAT2MAPTKDM4ELMNA | |
| SCHEMBL290194 | 0.78 | HPGD (0.42) | HPGDBCAT2MAPTKDM4ELMNA | |
| SCHEMBL29831842 | 0.78 | HPGD (0.42) | HPGDBCAT2MAPTKDM4ELMNA | |
| SCHEMBL4717730 | 0.69 | MAPT (0.48) | HPGDBCAT2MAPTLMNAGAA | |
| SCHEMBL4532187 | 0.69 | ALDH1A1 (0.49) | HPGDMAPTKDM4ELMNAGAA | |
| SCHEMBL290848 | 0.69 | KDM4E (0.45) | HPGDMAPTKDM4ELMNAGAA | |
| SCHEMBL5462039 | 0.69 | MAPT (0.49) | HPGDMAPTKDM4ELMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7498334-B2 | Pyrrolopyrimidines as phosphodiesterase VII inhibitors | MERCK PATENT GMBH (DE) | 2009-03-03 | — | — | US | claimed |
| EP-1458722-B1 | PYRROLOPYRIMIDINES AS PHOSPHODIESTERASE VII INHIBITORS | MERCK PATENT GMBH (DE) | 2008-10-15 | — | — | EP | claimed |
| US-20050059686-A1 | Pyrrolopyrimidines as phosphodiesterase vII inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2005-03-17 | — | — | US | claimed |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | MITODICURE GMBH (DE) | 2026-03-05 | — | — | US | disclosed |
| EP-4572765-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | Mitodicure GmbH (DE) | 2025-06-25 | — | — | EP | disclosed |
| WO-2024038089-A1 | USE OF A THERAPEUTIC AGENT WITH PHOSPHODIESTERASE-7 INHIBITORY ACTIVITY FOR THE TREATMENT AND PREVENTION OF DISEASES ASSOCIATED WITH CHRONIC FATIGUE, EXHAUSTION AND/OR EXERTIONAL INTOLERANCE | MITODICURE GMBH (DE) | 2024-02-22 | — | — | WO | disclosed |
| EP-4275752-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | Omeros Corporation (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION | 2023-04-13 | — | — | US | disclosed |
| CN-115192711-A | Use of PDE7 inhibitors for the treatment of movement disorders | 奥默罗斯公司 | 2022-10-18 | — | — | CN | disclosed |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | OMEROS CORPORATION (US) | 2022-10-11 | — | — | US | disclosed |
| CN-114984229-A | Treatment of addiction and impulse control disorders using PDE7 inhibitors | 奥默罗斯公司 | 2022-09-02 | — | — | CN | disclosed |
| US-8637528-B2 | Use of PDE7 inhibitors for the treatment of movement disorders | OMEROS CORPORATION (US) | 2014-01-28 | — | — | US | disclosed |
| WO-2013176877-A2 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | OMEROS CORPORATION (US) | 2013-11-28 | — | — | WO | disclosed |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2013-10-10 | — | — | US | disclosed |
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | OMEROS CORPORATION | 2012-05-10 | — | — | US | disclosed |
| EP-2427193-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | Omeros Corporation (US) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010129036-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-11-11 | — | — | WO | disclosed |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | OMEROS CORPORATION (US) | 2010-05-06 | — | — | US | disclosed |
| US-7498334-B2 | Pyrrolopyrimidines as phosphodiesterase VII inhibitors | MERCK PATENT GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| US-20050059686-A1 | Pyrrolopyrimidines as phosphodiesterase vII inhibitors | MERCK PATENT GESELLSCHAFT (DE) | 2005-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120115849-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | HPGD 2880/4885BCAT2 3270/4885MAPT 3149/4885 |
| US-11464785-B2 | Treatment of addiction and impulse-control disorders using PDE7 inhibitors | PDE7B, PDE4C, PDE4A | HPGD 2880/4885BCAT2 3270/4885MAPT 3149/4885 |
| US-20260060970-A1 | Use of a Therapeutic Agent with Phosphodiesterase-7 Inhibitory Activity for the Treatment and Prevention of Diseases Associated with Chronic Fatigue, Exhaustion and/or Exertional Intolerance | PDE5A, PDE4C, PDE12 | HPGD 3053/4885BCAT2 3910/4885MAPT 4622/4885 |
| US-20230110784-A1 | TREATMENT OF ADDICTION AND IMPULSE-CONTROL DISORDERS USING PDE7 INHIBITORS | PDE7B, PDE4C, PDE4A | HPGD 2880/4885BCAT2 3270/4885MAPT 3149/4885 |
| US-20130267502-A1 | Treatment of Addiction and Impulse-Control Disorders Using PDE7 Inhibitors | PDE7B, PDE4C, PDE4A | HPGD 2880/4885BCAT2 3270/4885MAPT 3149/4885 |
| US-20100113486-A1 | USE OF PDE7 INHIBITORS FOR THE TREATMENT OF MOVEMENT DISORDERS | PARK7, PDE7B, PDE7A | HPGD 2485/4885BCAT2 1767/4885MAPT 1951/4885 |
| US-20050059686-A1 | Pyrrolopyrimidines as phosphodiesterase vII inhibitors | PDE5A, PDE3B, PDE4A | HPGD 991/4885BCAT2 3686/4885MAPT 4701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.